BLA application for Tevimbra (tislelizumab) for first-line gastric or gastroesophageal junction cancers accepted by FDA – BeiGene
BeiGene, Ltd. announced that the FDA has accepted a Biologics License Application (BLA) for Tevimbra (tislelizumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of patients… read more.